Prolap 3 Tablet
Sold by Pharmigrow
PKR 1,250.00
View at Pharmigrow- Store
- pharmigrow.com
- Brand
- Pharmigrow
- Collected
- 2026-11-19
From the retailer
Homeopathic combination targeting 1st & 2nd degree uterine prolapse, menstrual cramps, pelvic pain, habitual abortion support and related pelvic complaints. KEY INGREDIENTS (Per Tablet): Aletris Far Q (EHPI) 19 mg; Ashoka Q (EHPI) 20 mg; Alfalfa Q (EHPI) 18 mg; Avena Sativa Q (EHPI) 17 mg; Helonias Q (EHPI) 19 mg; Scrophularia Q (EHPI) 18 mg; Kreasotum 30 (EHP) 15 mg; Ipecac 6x (EHP) 12 mg; Acid phos 6x (EHPI) 12 mg; Kali phos Ex (EHPI) 15 mg; Mag phos 6x (EHPI) 15 mg; Nat phos Ex (EHPI) 20 mg. DOSAGE: Mild–moderate: 1 tablet BID for 6–8 weeks. Severe: 1 tablet TID for 8–12 weeks or as directed by a healthcare professional. INSTRUCTIONS: Keep out of reach of children. Protect from light and moisture. Store in a cool, dry place.
How It Works
Synergistic homeopathic botanicals aim to support pelvic tissue tone, reduce spasmodic pain and assist symptomatic relief in pelvic floor conditions.
Key Benefits
✔
Supports symptomatic management of uterine prolapse
✔
Relieves menstrual cramps and pelvic discomfort
✔
Adjunct support for pelvic and reproductive concerns
Active Ingredients (Per Tablet)
Aletris Far Q (EHPI):
19 mg
Ashoka Q (EHPI):
20 mg
Alfalfa Q (EHPI):
18 mg
Avena Sativa Q (EHPI):
17 mg
Helonias Q (EHPI):
19 mg
Scrophularia Q (EHPI):
18 mg
Kreasotum 30 (EHP):
15 mg
Ipecac 6x (EHP):
12 mg
Acid phos 6x (EHPI):
12 mg
Kali phos Ex (EHPI):
15 mg
Mag phos 6x (EHPI):
15 mg
Nat phos Ex (EHPI):
20 mg
Dosage
Follow the stated dosing regimen or your clinician’s instructions for pelvic conditions.
Usage Instructions
Store in a cool, dry place
Protect from light & moisture
Keep out of reach of children
Safety
Use as adjunctive care; consult a gynecologist for diagnosed prolapse or surgical indications.
Frequently Asked Questions
❓
What is Prolap 3?
A homeopathic tablet for symptomatic pelvic and prolapse-related complaints.
⚕️
How long to take it?
Dosing varies by severity—commonly 6–12 weeks; follow healthcare guidance.
👤
Who should use it?
Patients with mild–moderate pelvic floor symptoms as part of a clinician-led plan.